Table 2 Relationship between clinicopathological features and extent of necrosis in 73 patients with CNC
From: Clinicopathological study of centrally necrotizing carcinoma of the breast
Clinicopathological feature | Case | ≥30% but <50% necrosis | ≥50% but <70% necrosis | ≥70% necrosis | P | |
|---|---|---|---|---|---|---|
(7, 9.6%) | (25, 34.3%) | (41, 56.2%) | ||||
IDC | Grade 3 | 67 | 7 (100.0%) | 23 (92.0%) | 37 (82.2%) | 0.685 |
Grade 2 | 6 | 0 (0.0%) | 2 (8.0%) | 4 (9.8%) | 0.685 | |
Grade 1 | 0 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | — | |
Ductal carcinoma in situ | 36 | 4 (57.1%) | 13 (52.0%) | 19 (46.3%) | 0.823 | |
Mucinous carcinoma | 5 | 1 (14.3%) | 3 (12.0%) | 1 (2.4%) | 0.235 | |
Intraductal papillary carcinoma | 1 | 0 (0.0%) | 0 (0.0%) | 1 (2.4%) | 0.673 | |
Invasive micropapillary carcinoma | 2 | 0 (0.0%) | 1 (4.0%) | 1 (2.4%) | 0.835 | |
Metaplasia | 6 | 0 (0.0%) | 4 (16.0%) | 2 (4.9%) | 0.198 | |
Myxoid stroma | 28 | 1 (14.3%) | 11 (44.0%) | 16 (39.0%) | 0.357 | |
Lymphocytic infiltration | 53 | 5 (71.4%) | 17 (68.0%) | 31 (75.6%) | 0.796 | |
Granulation tissue proliferation | 49 | 3 (42.9%) | 19 (76.0%) | 27 (65.9) | 0.248 | |
Vascular invasion | 10 | 0 (0.0%) | 4 (16.0%) | 6 (14.6%) | 0.534 | |
Perineuronal invasion | 5 | 1 (14.3%) | 1 (4.0%) | 3 (7.3%) | 0.625 | |
Expression of myoepithelial markers | 43 | 4 (57.1%) | 19 (76.0%) | 20 (48.8%) | 0.092 | |
Expression of basal-like markers | 52 | 5 (71.4%) | 22 (88.0%) | 25 (61.0%) | 0.063 | |
Molecular classification | Basal-like subtype | 37 | 3 (42.9%) | 9 (36.0%) | 25 (61.0%) | 0.132 |
Luminal A | 20 | 3 (42.9%) | 9 (36.0%) | 8 (19.5%) | 0.217 | |
Luminal B | 7 | 1 (14.3%) | 5 (20.0%) | 1 (2.4%) | 0.057 | |
HER2-overexpressing | 6 | 0 (0.0%) | 0 (0.0%) | 6 (14.6%) | 0.078 | |
Null subtype | 3 | 0 (0.0%) | 1 (4.0%) | 2 (4.9%) | 0.834 | |
Disease progression | 11 | 1 (14.3%) | 2 (8.0%) | 8 (19.5%) | 0.796 | |